Dr. med. Patrick Schmid
Infektiologie | Infektionsprävention | Reisemedizin · Dept. I
Barriers to interferon-alpha therapy are higher in intravenous drug users than in other patients with acute hepatitis C
Broers B, Helbling B, François A, Schmid P, Chuard C, Hadengue A, Negro F, Swiss Association for the Study of the Liver (SASL 18). Barriers to interferon-alpha therapy are higher in intravenous drug users than in other patients with acute hepatitis C. Journal of hepatology 2005; 42:323-8.
01.03.2005Barriers to interferon-alpha therapy are higher in intravenous drug users than in other patients with acute hepatitis C
01.03.2005Journal of hepatology 2005; 42:323-8
Broers Barbara, Helbling Beat, François Anne, Schmid Patrick, Chuard Christian, Hadengue Antoine, Negro Francesco, Swiss Association for the Study of the Liver (SASL 18)
Interferon alpha-2a Plus Ribavirin 1,000/1,200 mg versus Interferon alpha-2a Plus Ribavirin 600 mg for Chronic Hepatitis C Infection in Patients on Opiate Maintenance Treatment: An Open-Label Randomized Multicenter Trial
Schmid P. Interferon alpha-2a Plus Ribavirin 1,000/1,200 mg versus Interferon alpha-2a Plus Ribavirin 600 mg for Chronic Hepatitis C Infection in Patients on Opiate Maintenance Treatment: An Open-Label Randomized Multicenter Trial - M. Huber, R. Weber, R. Oppliger, P. Vernazza, P. Schmid, P. Schönbucher, B. Bertisch, D. Meili and E. L. Renner. Infection 2005; Volume 33:25-29.
01.02.2005Interferon alpha-2a Plus Ribavirin 1,000/1,200 mg versus Interferon alpha-2a Plus Ribavirin 600 mg for Chronic Hepatitis C Infection in Patients on Opiate Maintenance Treatment: An Open-Label Randomized Multicenter Trial
01.02.2005Infection 2005; Volume 33:25-29
Schmid Patrick